# GLP-1 use reaches new high in US — retained record

> Retained news record from news:semafor.

Canonical: https://highsignal.app/data/records/cfb9c1274ac465d7

[← sources](https://highsignal.app/data)


source: [news](https://highsignal.app/data/news) (news:semafor)  published 2026-07-08 22:46 ingested 2026-07-09 09:31

[original source ↗](https://www.semafor.com/article/07/08/2026/glp-1-use-reaches-new-high-in-us)

## retained text



```
The percentage of US citizens currently taking GLP-1 drugs such as Wegovy for weight loss has almost quadrupled to 11% from 3% in 2024. A further 4% of Americans say they’ve used the drugs in the past, Gallup polling found.
Meanwhile, US obesity rates, which peaked in 2022 at 39.9%, fell further to 36.4%, suggesting, although not proving, a causal link.
Early research hints at other benefits of the drugs, which were originally used for diabetes: A small trial this year found they can help treat alcohol abuse, while also appearing to reduce coronary disease risk over and above the benefits caused by losing weight.
```



document fetched 2026-07-09 09:31 · canonical https://semafor.com/article/07/08/2026/glp-1-use-reaches-new-high-in-us